Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites

J Hepatol. 2020 Dec;73(6):1404-1414. doi: 10.1016/j.jhep.2020.05.011. Epub 2020 May 21.

Abstract

Background & aims: The safety of non-selective β-blockers (NSBBs) has been questioned in refractory ascites (RA). We studied the effects of NSBBs on cardiac systolic function, systemic hemodynamics, and renal perfusion pressure (RPP) and function in patients with diuretic-responsive ascites (DRA) and RA.

Methods: We performed a prospective pre-post repeated-measures study in cirrhotic patients, 18 with DRA and 20 with RA on NSBBs for variceal bleeding prophylaxis. Systolic function (by ejection intraventricular pressure difference [EIVPD]), hepatic venous pressure gradient (HVPG), cardiopulmonary pressures, RPP, and sympathetic activation were measured at baseline and after 4 weeks of propranolol.

Results: EIVPD was elevated at baseline (RA 4.5 [2.8-5.7] and DRA 4.2 [3.1-5.7] mmHg; normal 2.4-3.6 mmHg) and directly related to the severity of vasodilation and sympathetic activation. NSBBs led to similar reductions in heart rate and HVPG in both groups. NSBBs reduced EIPVD in RA but not in DRA (-20% vs. -2%, p <0.01). In RA, the NSBB-induced reduction in EIPVD correlated with the severity of vasodilation and with higher plasma nitric oxide, norepinephrine and IL-6 (r >0.40, all p <0.05). NSBBs reduced RPP in both groups, but impaired renal function only in patients with RA. Reduced EIPVD correlated with decreases in RPP and estimated glomerular filtration rate (r >0.40, all p <0.01). After NSBB treatment, RPP dropped below the threshold of renal flow autoregulation in 11 of the 20 (55%) patients with RA, including the 4 fulfilling the criteria for HRS-AKI.

Conclusion: Renal perfusion and function depend critically on systolic function and sympathetic hyperactivation in RA. NSBBs blunt the sympathetic overdrive, hamper cardiac output, lower RPP below the critical threshold and impair renal function. β-blockade should be used cautiously or even avoided in patients with RA.

Lay summary: We have identified the mechanisms by which non-selective beta-blockers could impair survival in patients with refractory ascites. We show that peripheral vasodilation and sympathetic activation lead to increased left ventricle systolic function in patients with cirrhosis and ascites, which acts as an adaptive mechanism to maintain renal perfusion. When ascites becomes refractory, this compensatory cardiac response to vasodilation is critically dependent on sympathetic hyperactivation and is hardly able to maintain renal perfusion. In this setting, β-blockade blunts the sympathetic overdrive of cardiac function, hampers cardiac output, lowers renal perfusion pressure below the critical threshold and impairs renal function.

Trial registration: ClinicalTrials.gov NCT02163512.

Keywords: Cirrhosis; Cirrhotic cardiomyopathy; Hepatorenal syndrome; Inotropic heart dysfunction; Portal hypertension; Renal perfusion pressure; Resistive renal index; Systolic dysfunction; Variceal bleeding; Window hypothesis.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology*
  • Ascites* / etiology
  • Ascites* / physiopathology
  • Female
  • Glomerular Filtration Rate / drug effects
  • Heart Function Tests / methods*
  • Hemodynamics / drug effects
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control
  • Humans
  • Hypertension, Portal* / etiology
  • Hypertension, Portal* / physiopathology
  • Hypertension, Portal* / prevention & control
  • Kidney Function Tests / methods
  • Liver / blood supply
  • Liver / drug effects
  • Liver Cirrhosis* / complications
  • Liver Cirrhosis* / diagnosis
  • Liver Cirrhosis* / physiopathology
  • Male
  • Middle Aged
  • Sympathetic Nervous System / drug effects

Substances

  • Adrenergic beta-Antagonists

Associated data

  • ClinicalTrials.gov/NCT02163512